Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

KATching-Up on Small Molecule Modulators of Lysine Acetyltransferases
Roman P. Simon, Dina Robaa, Zayan Alhalabi, et al.
Journal of Medicinal Chemistry (2015) Vol. 59, Iss. 4, pp. 1249-1270
Closed Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

The Essential Medicinal Chemistry of Curcumin
Kathryn M. Nelson, Jayme L. Dahlin, Jonathan Bisson, et al.
Journal of Medicinal Chemistry (2017) Vol. 60, Iss. 5, pp. 1620-1637
Open Access | Times Cited: 1597
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
Loren Lasko, Clarissa G. Jakob, Rohinton Edalji, et al.
Nature (2017) Vol. 550, Iss. 7674, pp. 128-132
Open Access | Times Cited: 656
Modulation of cellular processes by histone and non-histone protein acetylation
Maria Shvedunova, Asifa Akhtar
Nature Reviews Molecular Cell Biology (2022) Vol. 23, Iss. 5, pp. 329-349
Closed Access | Times Cited: 513
The Significance of Mono‐ and Dual‐Effective Agents in the Development of New Antifungal Strategies
Cengiz Zobi, Öztekin Algül
Chemical Biology & Drug Design (2025) Vol. 105, Iss. 1
Open Access | Times Cited: 2
Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors
Yaxi Yang, Rukang Zhang, Zhaojun Li, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 3, pp. 1337-1360
Closed Access | Times Cited: 110
Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors
Jayme L. Dahlin, Kathryn M. Nelson, Jessica M. Strasser, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 99
Targeting the acetylation signaling pathway in cancer therapy
Fabin Dang, Wenyi Wei
Seminars in Cancer Biology (2021) Vol. 85, pp. 209-218
Open Access | Times Cited: 65
Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at 16q11.2 and MAPT H1 loci
Marc P. M. Soutar, Daniela Melandri, Benjamin O’Callaghan, et al.
Brain (2022) Vol. 145, Iss. 12, pp. 4349-4367
Open Access | Times Cited: 48
Epigenetic Control of the Tumor Microenvironment
David L. Marks, Rachel Olson, Martín E. Fernández-Zapico
Epigenomics (2016) Vol. 8, Iss. 12, pp. 1671-1687
Open Access | Times Cited: 78
Epigenetic modulators as therapeutic targets in prostate cancer
Inês Graça, Eva Pereira-Silva, Rui Henrique, et al.
Clinical Epigenetics (2016) Vol. 8, Iss. 1
Open Access | Times Cited: 74
Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer
Hany Abdel-Hafiz
Diseases (2017) Vol. 5, Iss. 3, pp. 16-16
Open Access | Times Cited: 65
Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases
Michael R. Michaelides, Arthur F. Kluge, Michael A. Patane, et al.
ACS Medicinal Chemistry Letters (2017) Vol. 9, Iss. 1, pp. 28-33
Open Access | Times Cited: 63
ARID1A Mutations Promote P300-Dependent Endometrial Invasion through Super-Enhancer Hyperacetylation
Mike R. Wilson, Jake J. Reske, Jeanne Holladay, et al.
Cell Reports (2020) Vol. 33, Iss. 6, pp. 108366-108366
Open Access | Times Cited: 52
Targeting cancer using KAT inhibitors to mimic lethal knockouts
James A. L. Brown, Emer Bourke, Leif A. Eriksson, et al.
Biochemical Society Transactions (2016) Vol. 44, Iss. 4, pp. 979-986
Open Access | Times Cited: 60
Interrogating the Roles of Post-Translational Modifications of Non-Histone Proteins
Zakey Yusuf Buuh, Zhigang Lyu, Rongsheng E. Wang
Journal of Medicinal Chemistry (2017) Vol. 61, Iss. 8, pp. 3239-3252
Closed Access | Times Cited: 56
Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer
Yuqing Lu, Yuewen Yang, Guanghao Zhu, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 11, pp. 3360-3382
Open Access | Times Cited: 14
Small molecules as tools to study the chemical epigenetics of lysine acetylation
Matthias Schiedel, Stuart J. Conway
Current Opinion in Chemical Biology (2018) Vol. 45, pp. 166-178
Closed Access | Times Cited: 39
Lifespan-increasing drug nordihydroguaiaretic acid inhibits p300 and activates autophagy
Tuğsan Tezil, Manish Chamoli, Che-Ping Ng, et al.
npj Aging and Mechanisms of Disease (2019) Vol. 5, Iss. 1
Open Access | Times Cited: 37
Integration of Epigenetic Mechanisms into Non-Genotoxic Carcinogenicity Hazard Assessment: Focus on DNA Methylation and Histone Modifications
Daniel Desaulniers, Paule Vasseur, Abigail Jacobs, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 20, pp. 10969-10969
Open Access | Times Cited: 32
Protein Acetyltransferases Mediate Bacterial Adaptation to a Diverse Environment
Aiswarya Dash, Rahul Modak
Journal of Bacteriology (2021) Vol. 203, Iss. 19
Open Access | Times Cited: 28
Histone modification and histone modification-targeted anti-cancer drugs in breast cancer: Fundamentals and beyond
Jianwei Feng, Xinyue Meng
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 22
Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies
Jinshou Yang, Feihan Zhou, Xiyuan Luo, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Acetylation and deacetylation dynamics in stress response to cancer and infections
Lili Li, Yanqiong Zeng, Genhong Cheng, et al.
Seminars in Immunology (2025) Vol. 78, pp. 101957-101957
Closed Access
Comprehensive Analysis of Cancer-Proteogenome to Identify Biomarkers for the Early Diagnosis and Prognosis of Cancer
Hem D. Shukla
Proteomes (2017) Vol. 5, Iss. 4, pp. 28-28
Open Access | Times Cited: 35
The STAT3 inhibitor Stattic acts independently of STAT3 to decrease histone acetylation and modulate gene expression
Dipak K. Poria, Namratha Sheshadri, Kuppusamy Balamurugan, et al.
Journal of Biological Chemistry (2020) Vol. 296, pp. 100220-100220
Open Access | Times Cited: 29
Page 1 - Next Page

Scroll to top